CONSHOHOCKEN, PA--(Marketwire - November 22, 2011) - NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present a company overview at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011, at 4:00 p.m. EST. The conference is being held at The New York Palace Hotel in New York, NY.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company’s website for 90 days following the presentation.
About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe’s lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Contact Information:
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130
